Skip to main content
. 2022 Feb 6;8(1):100916. doi: 10.1016/j.adro.2022.100916

Figure 2.

Fig 2

Receiver operating characteristic curves show improved performance in discriminating pseudoprogression from recurrent tumor for the radiomics + O6-methylguanine–DNA methyltransferase (MGMT) (blue) classifier than for the radiomics only (yellow) classifier.